Novo Nordisk has received accelerated approval for Wegovy, the first GLP-1 therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Raluca Ioana Draghici
International
www.shutterstock.com
Always see our news on Google
The FDA has fast-tracked approval of Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), affecting 5% of US adults. This is the first GLP-1 class therapy approved for MASH aimed at improving liver function. Preliminary studies have shown promising results, and Novo Nordisk has already applied for approval in Europe and Japan, expecting final trial results in 2029.
Sources
Latest News
22:57
Traian Băsescu says that AUR "has reached the end of its growth potential" and will have to explain "the money it gave to television stations"
22:50
Paramount Skydance and Warner Bros Discovery will form Skydance after the completion of a $110 billion deal
22:36
The sixth day of protests at the Central Detention Center: Supporters of Călin Georgescu demand his release
22:14
Traian Băsescu, regarding the government crisis: “They have no solution left except an independent prime minister”
21:56
Britain’s Green Party voted to classify Zionism as racism / Israel accuses the party of legitimizing terrorism
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
